Healthcare Sector

India is the world's largest provider of generic medications, accounting for around 20% of worldwide supply.

Indraprastha Medical maintains two hospitals: one in New Delhi and one in Noida. It is backed by the Delhi government and Apollo Hospitals.

The business would work together with the USFDA to resolve the concerns, it announced.

The company's board of directors will meet on Tuesday, May 7, 2024, to consider and approve the audited standalone and consolidated financial results.

The pharmaceutical stock was offered on public markets in May of last year, at a 20% premium to its issue price of ₹1,080.

Rodolfo Hrosz, Managing Director of Sanofi India Limited, emphasized that their CNS products hold leading positions within their respective categories.

He will be located in Mumbai and would be in charge of Lupin's technical operations.

Indranil Sen has resigned to seek possibilities outside of the organisation.

As part of the agreement, around 430 people from the company are scheduled to migrate to Eris.

Against its annual contracted value of USD50m supplies for Librela, Syngene has supplied USD94m worth of Librela to Zoetis over the past 13 months, which likely implies that Librela supplies to Zoetis will continue to taper off in CY24 and will present a tough base for Syngene going ahead. Syngene shipped just USD2m worth of Librela in Feb’24 vs USD21/13m in Dec’23/Jan’24 respectively.